Last reviewed 2026-06-01 · How we verify

TTAC-0001 and pembrolizumab combination

PharmAbcine · Phase 1 active Small molecule ✓ Verified Jun 2026

TTAC-0001 and pembrolizumab combination is a Small molecule drug developed by PharmAbcine. It is currently in Phase 1 development.

TTAC-0001 is being studied in combination with pembrolizumab for the treatment of Triple Negative Breast Cancer, Metastatic Triple-Negative Breast Cancer, and Recurrent Glioblastoma. This combination is being investigated in a Phase Ib clinical trial to assess its safety and tolerability in patients with these conditions.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	TTAC-0001 and pembrolizumab combination
Sponsor	PharmAbcine
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

TTAC-0001 and pembrolizumab combination CI brief — competitive landscape report
TTAC-0001 and pembrolizumab combination updates RSS · CI watch RSS
PharmAbcine portfolio CI

Frequently asked questions about TTAC-0001 and pembrolizumab combination

What is TTAC-0001 and pembrolizumab combination?

TTAC-0001 and pembrolizumab combination is a Small molecule drug developed by PharmAbcine.

Who makes TTAC-0001 and pembrolizumab combination?

TTAC-0001 and pembrolizumab combination is developed by PharmAbcine (see full PharmAbcine pipeline at /company/pharmabcine).

What development phase is TTAC-0001 and pembrolizumab combination in?

TTAC-0001 and pembrolizumab combination is in Phase 1.

Manufacturer: PharmAbcine — full pipeline

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing